SYF2569263d775e4f58a2c9573fc46f06ecRegistry ID: 2024-517679-18-00|RecruitingPhase 4
Loading search results
interventional
N/A
1 country
1
To evaluate the effect of PPI’s on the structural integrity of the ESG
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 9, 2024
Actual (reported)the assess the effect of PPIs on the proportion of patients with “Intact ESG”, “open ESG” and “partially intact ESG” at 6 months of follow-up
to assess the effect of PPI on the proportion of patients with “intact ESG”, “partially intact ESG” and “open ESG”, separately, at 12 months of follow-up.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
ESOMEPRAZOLE
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION/INFUSION
View registry recordFormulated product
ESOMEPRAZOLE
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
GASTRO-RESISTANT TABLET
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
ESOMEPRAZOLE
Named ingredient: Esomeprazole
View registry recordESOMEPRAZOLE
Named ingredient: Esomeprazole
View registry recordFondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, 00168, Italy
Ivo Boskoski
First Submitted
October 9, 2024
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Sphenopalatine Ganglion Block to Prevent Shoulder Pain After Laparoscopic Bariatric Surgery
Contact the study team to confirm eligibility.